H.C. Wainwright analyst Robert Burns upgraded Fate Therapeutics (FATE) to Buy from Neutral with a $5 price target The firm views the early results ...
From cobras in the walls and chandeliers too grand to pass through doorways, this Halloween, designers recount the interior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback